Immunomodulation, IL-1 Inhibition, and Postoperative Incisional Pain
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
California
-
Stanford, California, Stati Uniti, 94305
- Stanford Hospital and Clinics
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-Patients 18 years of age and older presenting to the Stanford Preoperative Evaluation Clinic prior to elective orthopedic surgical procedures or elective vascular surgical procedures not involving the abdominal aorta or carotid arteries.
Exclusion Criteria:
Patients will be excluded from participation if they have one or more of the following conditions:
- Evidence of active local or systemic infection as demonstrated by fever, leukocytosis (white blood cell count > 11,000/ul), productive cough, new infiltrate on chest x-ray, or purulent drainage from any source
- End-stage renal disease
- A history of diabetic neuropathy
- A malignancy other than basal cell carcinoma of the skin or in situ carcinoma of the cervix within the previous 5 years
- Leukopenia (white blood cell count < 2,000/ul)
- Thrombocytopenia (platelet count < 100,000/ul)
- Abnormal liver function test result (aspartate aminotransferase or alanine aminotransferase level ≥1.5-fold the upper limit of normal)
- A history or infection with tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus
- Pregnant or breastfeeding
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore attivo: Anakinra
Two subcutaneous injections of anakinra (IL-1ra) were given, the first one hour prior to surgery and the second 24 hours after surgery.
|
An injection of 100 mg Anakinra was administered 1 hour prior to surgery and again 24 hours following surgery.
Altri nomi:
|
|
Comparatore placebo: Saline injection
Two subcutaneous injections of normal saline (same volume as the anakinra group injection) were given, the first one hour prior to surgery and the second 24 hours after surgery.
|
An injection of normal saline was administered 1 hour prior to surgery and again 24 hours following surgery.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Concentration Levels of Inflammatory Mediators IL-1 Receptor Antagonist (IL-1ra) Present in Human Wounds Following Surgery With and Without the Use of Anakinra.
Lasso di tempo: Up to 72 hours following surgery
|
Tissue samples were collected at the surgical wound site at 3 time points during the 1st 72 hours following surgery.
Tissue samples from subjects receiving placebo, and subjects receiving anakinra injections pre, and post op were analyzed for IL-1
|
Up to 72 hours following surgery
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants With Analgesic Consumption During the 72 Hours Following Surgery
Lasso di tempo: Up to 72 hours following surgery
|
Analgesic consumption is reported as the count of participants receiving each analgesic type. Comparisons between the placebo and active drug groups were made at the conclusion of the study. PCA/IV: Patient controlled Analgesia/ Intravenous |
Up to 72 hours following surgery
|
|
Post-operative Pain Intensity
Lasso di tempo: Up to 72 hours following surgery
|
Pain was measured on Day 1 and day 2 following surgery using a VAS scale at rest and on stimulation with Visual Analog Scale (VAS) of 1-10 (1=no pain and 10=worst pain)
|
Up to 72 hours following surgery
|
|
Count of Participants Experiencing Wound Infection in the Study From Surgery Till the Time of Discharge From the Hospital
Lasso di tempo: Up to 72 hours following surgery plus 3 weeks follow-up
|
Evaluation of the surgical wound for symptoms of wound infection was made every day during hospitalization.
Records from the first post-operative clinic visit were also evaluated for evidence of wound infection.
|
Up to 72 hours following surgery plus 3 weeks follow-up
|
|
Count of Participants With Venous Thrombosis After Surgery During Hospitalization
Lasso di tempo: Up to 72 hours following surgery plus 3 weeks follow-up
|
Evaluation of the surgical wound for symptoms of venous thrombosis was made every day during hospitalization.
Records from the first post-operative clinic visit were also evaluated for evidence of venous thrombosis.
|
Up to 72 hours following surgery plus 3 weeks follow-up
|
|
Assess Rates of Wound Dehiscence
Lasso di tempo: Up to 72 hours following surgery plus 3 weeks follow-up
|
Evaluation of the surgical wound for symptoms of wound dehiscence was made every day during hospitalization.
Records from the first post-operative clinic visit were also evaluated for evidence of wound dehiscence.
|
Up to 72 hours following surgery plus 3 weeks follow-up
|
|
Total Length of Hospital Stay
Lasso di tempo: Up to approximately 5 days maximum (admittance to discharge)
|
Total length of hospital stay for patients enrolled in the study.
|
Up to approximately 5 days maximum (admittance to discharge)
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Robert L Lobato, MD, Stanford U
Studiare le date dei record
Studia le date principali
Inizio studio
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- SU-10312011-8587
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .